

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignnia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/846,589	05/01/2001	Omolayo O. Famodu	BB1191 DIV	5132
23416	7590 09/11/2003			
CONNOLLY BOVE LODGE & HUTZ, LLP			EXAMINER	
P O BOX 2207 WILMINGTON, DE 19899			KERR, KATHLEEN M	
			ART UNIT	PAPER NUMBER
			1652	
			DATE MAILED: 09/11/2003	(6

Please find below and/or attached an Office communication concerning this application or proceeding.

t		Application No.	Applicant(s)		
		09/846,589	FAMODU ET AL.		
	Office Action Summary	Examiner	Art Unit		
		Kathleen M Kerr	1652		
Period fo	The MAILING DATE of this communication apr Reply	opears on the cover	sheet with the correspondence address		
THE II - Exter after - If the - If NO - Failui - Any r	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION usions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reperiod for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statuely received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, howeve	er, may a reply be timely filed num of thirty (30) days will be considered timely. X (6) MONTHS from the mailing date of this communication.		
1)🖂	Responsive to communication(s) filed on 24	June 2003 .			
2a) <u></u> □	This action is FINAL . 2b)⊠ T	his action is non-fina	al.		
3) 🗌 Dispositi	Since this application is in condition for allow closed in accordance with the practice unde on of Claims	vance except for for r Ex parte Quayle, 1	mal matters, prosecution as to the merits is 935 C.D. 11, 453 O.G. 213.		
4)🖾	Claim(s) 44-50 and 52-56 is/are pending in t	he application.			
•	4a) Of the above claim(s) is/are withdrawn from consideration.				
	Claim(s) 48 and 49 is/are allowed.				
6)⊠	Claim(s) <u>44-47,50 and 52-56</u> is/are rejected.				
	Claim(s) is/are objected to.				
8)	Claim(s) are subject to restriction and/	or election requirem	ent.		
	on Papers	,			
9)🛛 🗆	he specification is objected to by the Examin	er.			
10)∏ 7	he drawing(s) filed on is/are: a)□ acce	epted or b)⊡ objected	I to by the Examiner.		
	Applicant may not request that any objection to the	he drawing(s) be held	in abeyance. See 37 CFR 1.85(a).		
11)[] ז	he proposed drawing correction filed on	_ is: a)∏ approved	b) disapproved by the Examiner.		
	If approved, corrected drawings are required in re	• •	n.		
12)□ Т	he oath or declaration is objected to by the E	xaminer.			
Priority u	nder 35 U.S.C. §§ 119 and 120				
13)	Acknowledgment is made of a claim for foreig	n priority under 35 l	J.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:					
	1. Certified copies of the priority documents have been received.				
:	2. Certified copies of the priority documents have been received in Application No				
	3. Copies of the certified copies of the price application from the International Bree the attached detailed Office action for a list	ureau (PCT Rule 17	.2(a)).		
		-	J.S.C. § 119(e) (to a provisional application).		
a)	☐ The translation of the foreign language pr cknowledgment is made of a claim for domes	ovisional application	has been received.		
Attachment(
2) Notice 3) Inform	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 N	terview Summary (PTO-413) Paper No(s) otice of Informal Patent Application (PTO-152) ther:		
S. Patent and Tra TOL-326 (Re		ction Summary	Part of Paper No. 16		

Art Unit: 1652

DETAILED ACTION

Application Status

1. In response to the previous Office action, a non-Final rejection (Paper No. 11, mailed on February 21, 2003), Applicants filed a response and amendment received on June 24, 2003 (Paper No. 14). Said amendment cancelled Claim 51. Thus, Claims 44-50 and 52-56 are pending in the instant Office action and will be examined herein.

Priority

- 2. As previously noted, the instant application is granted the benefit of priority for the U.S. non-Provisional Application No. 09/352,990 filed on July 14, 1999 now USPN 6,255,090.
- 3. As previously noted, the instant application is not granted the benefit of priority for the U.S. Provisional Application No. 60/092,866 filed on July 15, 1998 because the instant application does not comply with the rules set out in 35 U.S.C. § 119 (e): namely, no common inventors are found between the instant application and the provisional application. Applicants comment in their remarks that Layo O. Morakinyo, an inventor on the provisional application, is the same person as Omolayo O. Famodu, an inventor of the instant application. A petition to this effect has been filed, but not decided. Until the petition is decided, this issue will be help in abeyance by the Examiner.

Information Disclosure Statement

4. The information disclosure statement (IDS) filed on June 24, 2003 (Paper No. 15) has been reviewed, and its references have been considered as shown by the Examiner's initials next to each citation on the attached copy.

Withdrawn - Objections to the Specification

- 5. Previous objection to the specification because the title is not descriptive is withdrawn by virtue of Applicants' amendment.
- 6. Previous objection to the Abstract is objected to for not completely describing the disclosed subject matter is withdrawn by virtue of Applicant's amendment.

Previous objection to the specification for now containing an inappropriate amendment is withdrawn by virtue of Applicants' amendment returning page 9 to its originally filed text and page 6 to the amended text.

Maintained - Objections to the Specification

7. Previous objection to the specification for appropriate lacking continuity data in the first paragraph is maintained due to the question of claiming priority to the provisional application (see Priority section above). Appropriate amendment may be due to the specification upon decision of the petition noted above (see M.P.E.P. § 201.11).

Art Unit: 1652

Withdrawn - Claim Objections

8. Previous objection to Claim 51 under 37 C.F.R. § 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim is withdrawn by virtue of Applicants' cancellation of said claim.

Withdrawn - Claim Rejections - 35 U.S.C. § 112

- 9. Previous rejection of Claim 51 under 35 U.S.C. § 112, second paragraph, as being indefinite for being unclear is withdrawn by virtue of Applicants' cancellation of said claim.
- 10. Previous rejection of Claim 51 under 35 U.S.C. § 112, first paragraph, written description, is withdrawn by virtue of Applicants' cancellation of said claim.

Withdrawn - Claim Rejections - 35 U.S.C. § 102

11. Previous rejection of Claim 51 under 35 U.S.C. § 102(e) as being anticipated by Lalgudi et al. is withdrawn by virtue of Applicants' cancellation of said claim.

NEW REJECTIONS

Claim Rejections - 35 U.S.C. § 112

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

12. Claims 44-47, 50, and 52-56 are rejected under 35 U.S.C. § 112, first paragraph, scope of enablement, because the specification, while being enabling for polynucleotides that encode SEQ

Art Unit: 1652

ID NO:10, does not reasonably provide enablement for polynucleotides with low sequence identity with respect to the disclosed encoding polynucleotide, SEQ ID NO:9. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. The amount of experimentation required of one of skill in the art to make the claimed invention to the full extent of its scope is undue.

The factors to be considered in determining whether undue experimentation is required are summarized In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988). The court in Wands states: "Enablement is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue,' not 'experimentation.' " (Wands, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations." (Wands, 8 USPQ2d 1404). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2) the amount or direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims. While all of these factors are considered, a sufficient amount for a prima facie case is discussed below.

Art Unit: 1652

The instant specification teaches various tRNA synthetases (Asp, Cys, Trp, and Tyr) from plants, specifically Zea mays, Oryza sativa, Triticum aestivum and Glycine max. The specification teaches three Cys-tRNA synthetases from plants (from O. sativa, G. max, and Z. mays); the instant claims are drawn to polynucleotides related to the Cys tRNA synthetase from Zea mays (SEQ ID NOs: 9 and 10). The art includes several examples of Cys tRNA synthetase encoding genes; however their sequence relatedness is very limited as noted below in "Examiner's Comments". Moreover, the relatedness between the plant Cys-tRNA synthetases disclosed in the instant specification is also limited and not discussed as a genus, i.e., what structural components enable these sequences to encode plant Cys-tRNA synthetases as a group? The art fully enables any DNA encoding SEQ ID NO:10 based on the degeneracy of the genetic code. While the instant specification describes and enables means for identifying other Cys tRNA synthetase genes using hybridization methods, etc., these methods do not enable one of skill in the art to make all, or a relevant portion of, the polynucleotides within the scope of the claims because the ability to find a Cys tRNA synthetase gene, which is structurally related to SEQ ID NO:9, is not equivalent to the ability to make a Cys tRNA synthetase gene as required by the statute (i.e., "make and use"). No description in the specification or the art provides particular residues whose encoding is important within the disclosed sequence so that its Cys tRNA synthetase-nature is maintained. Thus, one of skill in the art would be unable to predict the structure of the other members of the genus in order to make such members. Therefore, the instant claims are not enabled to the full extent of their scope.

Art Unit: 1652

Summary of Pending Issues

13. The following is a summary of the issues pending in the instant application:

- a) The specification stands objected to for cited continuity data; relying on a petition related to the provisional application.
- b) Claims 44-47, 50, and 52-56 stand rejected under 35 U.S.C. § 112, first paragraph, scope of enablement.

Closest Prior Art and Examiner's Comments

- 14. The following is reiterated from the previous Office action:
- a) "The closest prior art identified by the Examiner is GenBank Accession Number AB009048, Arabidopsis thaliana genomic DNA, chromosome 5 (published December 2, 1997). This GenBank Accession Number teaches a 71,736 bp DNA sequence a portion of which having limited (<50%) similarity to a sequence encoding SEQ ID NO:10 (see attached alignment). This art is clearly not within the scope of Claims 44-50 and 52-56."
- b) "In addition to noting the above closest prior art, the Examiner is noting the following for clarity and completeness of the record. The instant claims are drawn to a polynucleotide that encodes a cysteinyl tRNA synthetase (Cys-tRS) and that is structurally related to SEQ ID NOs:9 (DNA) and/or 10 (amino acid). From *Zea mays* (corn), SEQ ID NO:10 is a 599 amino acid sequence, and SEQ ID NO:9 exactly encodes said sequence with 2085 base pairs. This sequence does *not* start with a methionine (or the less common valine) and does *not* end with a stop codon. The specification describes SEQ ID NO:10 as a cysteinyl-tRNA

Art Unit: 1652

synthetase by virtue of limited homology (40-45%) with putative Cys-tRS's from *H.* influenzae and *E. coli* (see Example 4).

Cys-tRS's in the art range in size from 489-750 amino acids in length, thus, SEQ ID NO:10 is within the art-defined range of enzymes. A putative Cys-tRS from *A. thaliana* is only about 40% identical to that of *H. influenzae* and *E. coli*, as similarly described for the Zea mays sequence in the instant specification. From these data, the putative assignment of Cys-tRS functionality for SEQ ID NO:10 is reasonable and fulfills the utility requirement.

Other plant Cys-tRS sequences in the instant application have low homology to a sequence encoding SEQ ID NO:10; *Oryza sativa* at 76% and *Glycine max* at 47% (see attached alignments). Such plant sequences would be expected to have a higher homology to the *Zea mays* sequence (see Peeters *et al.*). Moreover, in GenBank Accession Number AY104190, a slightly longer DNA sequence is disclosed by DuPont's maize mapping group that is 2120 base pairs long encompassing SEQ ID NO:9 exactly end-to-end (see attached alignment); in this case, DuPont does **NOT** identify the sequence as a Cys-tRS. It is noted that in AAD07974 just 5' of the SEQ ID NO:9 corresponding base pairs is a "tga" stop codon and just 3' of SEQ ID NO:9 is a "tga" stop codon. Thus, it would seem that SEQ ID NO:9 is not a part of the full-length open reading frame. However, none of the above data taken alone or together are sufficient to form a *prima facie* case to discount the putative functional assignment of SEQ ID NO:10 by Applicants in the instant specification. Thus, the claims have utility and adequate written description."

Art Unit: 1652

Conclusion

Page 9

15. Claims 48 and 49 are allowed. Claims 44-47, 50, and 52-56 are not allowed for the reasons identified in the numbered sections of this Office action. Applicants must respond to the objections/rejections in each of the numbered sections in this Office action to be fully responsive in prosecution. The instant Office action is **non-final** due to the new grounds of rejection set forth herein.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kathleen M Kerr whose telephone number is (703) 305-1229. The examiner can normally be reached on Monday through Friday, from 8:30am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathupura Achutamurthy can be reached on (703) 308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

KMK

September 10, 2003

KathL L